Effects of the COVID-19 pandemic on the number and characteristics of public drug program beneficiaries in Ontario, Canada
Bouck Z, McCormack D, Tadrous M, Campbell T, Gomes T. Canadian Health Policy. 2024; Jul 22 [Epub ahead of print].
Publications
Cost evaluation of the Ontario virtual urgent care pilot program: population-based, matched cohort study
Tarride J-E, Hall JN, Mondoux S, Dainty KN, McCarron J, Paterson JM, Plumptre L, Borgundvaag E, Ovens H, McLeod SL. J Med Internet Res. 2024; 26:e50483. Epub 2024 Jul 15.
The association between alcohol retail access and health care visits attributable to alcohol for individuals with and without a history of alcohol-related health-care use
Myran DT, Friesen E, Talarico R, Gaudreault A, Taljaard M, Hobin E, Smith BT, Schwartz N, Giesbrecht N, Crépault J-F, Tanuseputro P, Manuel DG. 2024; May 28 [Epub ahead of print].
Multifetal pregnancy after implementation of a publicly funded fertility program
Velez MP, Soule A, Gaudet L, Pudwell J, Nguyen P, Ray JG. JAMA Netw Open. 2024; 7(4):e248496. Epub 2024 Apr 25.
Impact of the 2021 CKD-EPI eGFR equation on kidney care referral criteria in Ontario, Canada: a population-based cross-sectional study
McArthur E, Smith G, Sood MM, Blake PG, Brimble KS, Muanda FT, Garg AX, Dixon SN. Can J Kidney Health Dis. 2024; 11:20543581241229258. Epub 2024 Mar 23.
The PSY-SIM model: Using real-world data to inform healthcare policy for individuals with chronic psychotic disorders
de Oliveira C, Mason J, Luu L, Iwajomo T, Simbulan F, Kurdyak P, Pechlivanoglou P. Schizophr Bull. 2023; Dec 16 [Epub ahead of print].
Impact of non-medical cannabis legalization with market restrictions on health service use and incident cases of psychotic disorder in Ontario, Canada
Anderson KK, Rodrigues R, Le B, Mamun M, Archie S, Edwards J, Elton-Marshall T, Gilliland J, Myran DT, Palaniyappan L, Perlman CM, Seabrook JA, Murray RM, Shariff SZ. Int J Drug Policy. 2023; Dec 10 [Epub ahead of print].
Effect of a novel multicomponent intervention to improve patient access to kidney transplant and living kidney donation: the ENAKT LKD cluster randomized clinical trial
Garg AX, Yohanna S, Naylor KL, McKenzie SQ, Mucsi I, Dixon SN, Luo B, Sontrop JM, Beaucage M, Belenko D, Coghlan C, Cooper R, Elliott L, Getchell L, Heale E, Ki V, Nesrallah G, Patzer RE, Presseau J, Reich M, Treleaven D, Wang C, Waterman AD, Zaltzman J, Blake PG. JAMA Intern Med. 2023; Nov 3 [Epub ahead of print].
Cannabis-involved traffic injury emergency department visits after cannabis legalization and commercialization
Myran DT, Gaudreault A, Pugliese M, Manuel D, Tanuseputro P. JAMA Netw Open. 2023; 6(9):e2331551. Epub 2023 Sep 6.
Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: a cross-sectional time-series analysis
Chang A, Chaudhry S, McCormack D, Gomes T, Shivji A, Tadrous M. Can Pharm J (Ott). 2022; Oct 12 [Epub ahead of print].